Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 7/20 | 0.35 |
| ▸ | HEXB | P07686 | 1/20 | 0.35 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.34 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.34 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.34 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.31 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.31 |
| ▸ | PYGB | P11216 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CDA | P32320 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12899685 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRLMNATDP1OGA | |
| SCHEMBL12929255 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRLMNATDP1OGA | |
| SCHEMBL6974076 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRLMNATDP1OGA | |
| SCHEMBL14278422 | 0.93 | ALDH1A1 (0.34) | ALDH1A1TSHRLMNATDP1OGA | |
| SCHEMBL14302212 | 0.93 | ALDH1A1 (0.34) | ALDH1A1TSHRLMNATDP1OGA | |
| SCHEMBL14278421 | 0.93 | ALDH1A1 (0.34) | ALDH1A1TSHRLMNATDP1OGA | |
| SCHEMBL14302217 | 0.93 | ALDH1A1 (0.34) | ALDH1A1TSHRLMNATDP1OGA | |
| SCHEMBL14278423 | 0.87 | OGA (0.33) | ALDH1A1TSHRLMNATDP1OGA | |
| SCHEMBL12899657 | 0.82 | OGA (0.41) | ALDH1A1TSHRLMNATDP1OGA | |
| SCHEMBL7603749 | 0.82 | OGA (0.41) | ALDH1A1TSHRLMNATDP1OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415309-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGMENT PTY LTD (AT) | 2013-04-09 | — | — | US | disclosed |
| US-20120122811-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122811-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | ALDH1A1 2444/4885TSHR 4539/4885LMNA 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.